Mirae Asset Venture Investment has invested in Actis On Call, a U.S. biotechnology company, while continuing to invest in startups in the bio sector with high growth potential.

According to DeGuru, Actis Oncology completed the Series A expansion funding round worth $84 million on the 25th. Mirae Asset Venture Investment participated in the fund as a new investor.


Actis On Call is a bio-start-up established in 2019 that was spun off from DPM Capital in the U.S. It has also developed a platform for creating a marker treatment that can effectively remove tumors from cancer tissues. It has also partnered with Terra Power, founded by Microsoft founder Bill Gates, to cooperate from development to commercialization.

“Additional funds will help us develop our mini-protein program and enable us to invest more in development capabilities, supply chains, and distribution networks,” Oncology CEO Matthew Roden Actis told The Guru.

Mirae Asset Venture Investment also participated in Series A financing of A by Abelosterafutix this month. In this way, investment in promising startups in the bio sector is continuously expanding.